Chemotherapy in stage II nonseminomatous germ cell tumors of the testis: The institut Gustave roussy experience

Urologic Oncology: Seminars and Original Investigations

Volumn 1, Issue 5, 1995, Pages 175-183

  Culine, S ^a   Theodore, C ^a   Terrier Lacombe, M J ^a   Droz, J P ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

chemotherapy; lymphadenectomy; stage 11; Testicular tumors

Indexed keywords

EID: 58149363359     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/1078-1439(95)00062-3     Document Type: Article

References (40)

1. Treatment of testicular cancer A new and improved model
2. The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: The Indiana University experience (1965 to 1989)
3. No adjuvant chemotherapy in selected patients with pathologic stage 14 nonseminomatous germ cell tumors of the testis
4. Is adjuvant chemotherapy necessary for patients with stage B1 testicular cancer?
5. Primary chemotherapy for stage II nonseminomatous germ cell tumors of the testis
6. Prognostic factors in advanced nonseminomatous testicular cancer. A multivariate logistic regression analysis
7. A phase II trial of early intensive chemotherapy with autologous bone marrow transplantation in the treatment of poor prognosis nonseminomatous germ cell tumors
8. No evidence of a benefit of early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor-risk nonseminomatous germ cell tumors: Preliminary results of a randomized trial
9. High failure rate of carboplatin-etoposide combination in good-risk nonseminomatous germ cell tumours
10. Adjuvant vinblastine, actinomycin D, bleomycin, cyclophosphamide and cis-platinum chemotherapy regimen with and without maintenance in patients with resected stage IIB testis cancer
11. Stage Ii nonseminomatous testicular cancer: A 10-year experience
12. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer
13. Adjuvant chemotherapy of metastatic stage II nonseminomatous testis tumor
14. Adjuvant chemotherapy for stage If nonseminomatous germ cell cancer of the testis
15. Etoposide and cisplatin is effective adjuvant chemotherapy in patients with stage II nonseminomatous germ cell tumors following retroperitoneal lymph node dissection
16. Primary chemotherapy for clinical stage II nonseminomatous germ cell tumors of the testis: A follow-up of 50 patients
17. Stage II nonseminomatous germ cell tumors of the testis: An analysis of treatment options in patients with low volume retroperitoneal disease
18. Treatment options in clinical stage I non-seminomatous germ cell tumours of the testis: A wager on the future?
19. The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy
20. The management of patients with clinical stage A testicular nonseminomatous germ cell tumors and persistently elevated serologic markers
21. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with goodprognosis germ cell tumors
22. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: A Southeastern Cancer Study Group protocol
23. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: An Eastern Cooperative Oncology Group trial
24. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: A multiinstitutional study
25. A trial of carboplatin-based combination chemotherapy in good prognosis metastatic testicular non seminoma
26. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: A Southeastern Cancer Study Group and Southwest Oncology Group protocol
27. Treatment of goodrisk disseminated non-seminomatous germ cell tumours: The less bleomycin, the more cisplatin?
28. Treatment of testicular cancer and the development of secondary malignancies
29. Secondary tumours following etoposide containing therapy for germ cell cancer
30. Complications of post-chemotherapy retroperitoneal lymph node dissection
31. Complications of primary retroperitoneal lymph node dissection
32. Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer
33. Reassessment of the role of adjunctive surgical therapy in the treatment of advanced germ cell tumors
34. Residual abdominal masses after chemotherapy for nonseminomatous testicular cancer: Correlation of CT and histology
35. Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses?
36. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors Recommendations for patient selection
37. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: Multivariate analysis of individual patient data from six study groups
38. Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors
39. Cost and risk benefit in the management of clinical stage II nonseminomatous testicular tumors